Last updated on January 2020

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.


Brief description of study

To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.

Clinical Study Identifier: NCT02947165

Find a site near you

Start Over

Novartis Investigative Site

Hong Kong, Hong Kong
8.76miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.